Bayer AG annual ebitda
2022
2023
2024
2025
Bayer AG EBITDA Growth & History (BAYN)
Bayer AG's calculated EBITDA was €1.92B for fiscal 2025.
View full Bayer AG company overviewBayer AG annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €1.92B | −€6.89B | −78.19% |
| 2024 | 2024-12-31 | €8.81B | −€1.64B | −15.69% |
| 2023 | 2023-12-31 | €10.45B | −€2.58B | −19.83% |
| 2022 | 2022-12-31 | €13.03B | — | — |
Bayer AG quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €1.91B | €1.68B | +710.59% |
| Q1 2026 | 2026-03-31 | €4.72B | — | — |
| Q4 2025 | 2025-12-31 | −€2.61B | — | — |
| Q3 2025 | 2025-09-30 | €606.0M | — | — |
| Q2 2025 | 2025-06-30 | €236.0M | — | — |
Bayer AG ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Bayer AG's ebitda decreased from €13.03B to €1.92B, a change of −€11.11B. The latest reported quarter, Q2 2026, shows €1.91B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
